News

Date Title and Summary
Toggle Summary Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing
- Results Presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 - ATLANTA --(BUSINESS WIRE)--Apr. 2, 2019-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives
Toggle Summary Odonate Therapeutics Initiates CONTESSA TRIO
- Study Will Investigate Tesetaxel-Immuno-Oncology (IO) Combinations in Patients with Metastatic Triple-Negative Breast Cancer (TNBC) - - First Randomized Clinical Study to Compare Three Approved PD-(L)1 Inhibitors - - Study Also Will Investigate Tesetaxel Monotherapy in Elderly Patients with HER2
Toggle Summary Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
SAN DIEGO --(BUSINESS WIRE)--Mar. 6, 2019-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care
Toggle Summary Odonate Therapeutics Announces Initiation of CONTESSA 2, a Phase 2 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane
SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2019-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has initiated CONTESSA 2, a multinational,
Toggle Summary Odonate Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019
- In Preclinical Testing, Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time - SAN DIEGO --(BUSINESS WIRE)--Feb. 28, 2019-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class
Toggle Summary Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018
SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2019-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months
Toggle Summary Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018
SAN DIEGO --(BUSINESS WIRE)--Oct. 23, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended
Toggle Summary Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018
SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended
Toggle Summary Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer
- Results from Multicenter Phase 2 Study Presented at The 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting - CHICAGO --(BUSINESS WIRE)--Jun. 2, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that
Toggle Summary Odonate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
SAN DIEGO --(BUSINESS WIRE)--May 31, 2018-- Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will present at the Jefferies 2018 Global
Back to Top